DR. ANDREA ERICKSON BEST, DO
Osteopathic Medicine at Buena Rd, Green Oaks, IL
License number
Illinois 036096838
Category
Osteopathic Medicine
Type
General Practice
Address
Address
510 Buena Rd, Green Oaks, IL 60045
Phone
(847) 846-3414
Personal information
See more information about ANDREA ERICKSON BEST at radaris.comName
Address
Phone
510 Buena Rd, Lake Forest, IL 60045
510 Buena Rd, Lake Forest, IL 60045
688 Old Elm Rd, Lake Forest, IL 60045
688 E Old Elm Rd, Lake Forest, IL 60045
611 Cuyler Ave, Oak Park, IL 60302
Professional information
See more information about ANDREA ERICKSON BEST at trustoria.com
Dr. Andrea E Best, Lake Forest IL - DO (Doctor of Osteopathic Medicine)
Dr. Andrea E Best, Lake Forest IL - DO (Doctor of Osteopathic Medicine)
Specialties:
Family Medicine
Address:
510 Buena Rd, Lake Forest 60045
(847) 846-3414 (Phone)
(847) 846-3414 (Phone)
Certifications:
Family Practice, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Chicago College of Osteopathic Medicine / Midwestern University
Graduated: 1995
Chicago College of Osteopathic Medicine / Midwestern University
Graduated: 1995
Extended Release Hydrocodone Acetaminophen And Related Methods And Uses Thereof
Extended Release Hydrocodone Acetaminophen And Related Methods And Uses Thereof
US Patent:
2010001, Jan 14, 2010
Filed:
Feb 4, 2009
Appl. No.:
12/365639
Inventors:
Rita I. Jain - Evanston IL, US
Andrea E. Best - Lake Forest IL, US
Earle Lockhart - Lake Bluff IL, US
Steven E. Marx - Hoffman Estates IL, US
James W. Thomas - Grayslake IL, US
Pamela Giang Vo - Gurnee IL, US
Andrea E. Best - Lake Forest IL, US
Earle Lockhart - Lake Bluff IL, US
Steven E. Marx - Hoffman Estates IL, US
James W. Thomas - Grayslake IL, US
Pamela Giang Vo - Gurnee IL, US
Assignee:
ABBOTT LABORATORIES - ABBOTT PARK IL
International Classification:
A61K 31/4355
US Classification:
514282
Abstract:
The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily.
Antibodies Against Nerve Growth Factor (Ngf) With Enhanced In Vivo Stability
Antibodies Against Nerve Growth Factor (Ngf) With Enhanced In Vivo Stability
US Patent:
2010027, Nov 4, 2010
Filed:
May 4, 2010
Appl. No.:
12/773488
Inventors:
John Powell - Cambridgeshire, GB
Duncan Casson - Royston, GB
Mark Maginn - Wilburton, GB
Wei Liu - Mundelein IL, US
Sandeep Dutta - Gurnee IL, US
Andrea Best - Lake Forest IL, US
Jerry A. Hall - Gurnee IL, US
Duncan Casson - Royston, GB
Mark Maginn - Wilburton, GB
Wei Liu - Mundelein IL, US
Sandeep Dutta - Gurnee IL, US
Andrea Best - Lake Forest IL, US
Jerry A. Hall - Gurnee IL, US
Assignee:
PANGENETICS 110 BV - Utrecht
International Classification:
A61K 39/395, C07K 16/18, C12N 15/63, C12N 5/10, A61P 25/00
US Classification:
4241581, 5303892, 5303873, 4353201, 435325, 435 696
Abstract:
The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
Antibodies Against Nerve Growth Factor (Ngf) With Enhanced In Vivo Stability
Antibodies Against Nerve Growth Factor (Ngf) With Enhanced In Vivo Stability
US Patent:
2013029, Nov 7, 2013
Filed:
May 2, 2013
Appl. No.:
13/886104
Inventors:
Duncan Casson - Royston, GB
Mark Maginn - Wilburton, GB
Wei Liu - Mundelein IL, US
Sandeep Dutta - Gurnee IL, US
Andrea Best - Lake Forest IL, US
Jerry A. Hall - Gurnee IL, US
Mark Maginn - Wilburton, GB
Wei Liu - Mundelein IL, US
Sandeep Dutta - Gurnee IL, US
Andrea Best - Lake Forest IL, US
Jerry A. Hall - Gurnee IL, US
Assignee:
Abbott Research B.V. - Zwolle
International Classification:
C07K 16/22
US Classification:
4241581, 5303892, 4353201, 435336, 435 696
Abstract:
The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.